Meliglix 25 Mg

Sitagliptin, the active ingredient in Meliglix, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a 25 mg tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Meliglix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU markets.

Sitagliptin is used in the treatment of type 2 diabetes, a metabolic disorder characterized by insulin resistance and impaired glucose regulation. - Type 2 diabetes mellitus (monotherapy): improves fasting and post‑prandial glucose levels as part of diet and exercise. - Type 2 diabetes mellitus (combined with metformin): provides additional HbA1c reduction when added to metformin therapy. - Type 2 diabetes mellitus (combined with insulin): assists in achieving target glycaemic levels alongside insulin therapy.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, potentially severe. - Severe allergic reaction: including angioedema or anaphylaxis. - Joint pain: unexplained arthralgia that may require medical evaluation.

Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic impairment: use with caution and monitor liver function tests. Cardiovascular disease: monitor for any adverse cardiac events. Pregnancy and lactation: safety not established; assess risk versus benefit. Concomitant use with other DPP‑4 inhibitors: avoid combined therapy due to increased adverse‑event risk. Store at ambient temperature: keep in the original pack, protect from moisture.

Major Interactions (Avoid): - Other DPP‑4 inhibitors: combined effect may increase risk of adverse events. - Strong diuretics in renal impairment: may affect sitagliptin clearance.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Rifampin: may reduce sitagliptin plasma concentrations. - Digoxin: may increase digoxin levels. - ACE inhibitors: monitor renal function when used together.